The Bioorganic Chemistry of RNA editing by ADARs View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2000-2019

FUNDING AMOUNT

3906468 USD

ABSTRACT

? DESCRIPTION (provided by applicant): The RNA editing ADAR enzymes convert adenosines to inosines in RNA. This phenomenon is widespread with > 15,000 A to I sites known in human transcripts. Since inosine is decoded as guanosine during translation, this modification can lead to changes in the meaning of codons (recoding). There are at least 50 different A to I sites in human mRNAs that cause recoding and recoding is common in the nervous system. Indeed, ADARs are necessary for a properly functioning nervous system and are known to regulate behavior in metazoans. Mutations in the human ADAR1 gene cause the skin disorder Dyschromatosis Symmetrica Hereditaria (DSH) and the autoimmune disease Aicardi-Goutieres Syndrome (AGS). Also, hyper editing has been observed at certain sites in cancer cells, such as in the mRNA for AZIN1 (antizyme inhibitor 1). In contrast however, hypo editing is observed in the glioma- associated ongene 1 (Gli1), a transcription factor important in the Hedgehog signaling pathway considered a therapeutic target in several types of cancer. Despite the significance of this form of regulation of RNA structure and function, our understanding of the mechanism of A to I editing is deficient. For instance, the selectivity for specific adenosines within ADAR substrates remains difficult to fully explain. Furthermore, pharmacological methods for controlling RNA editing at specific sites do not currently exist. In this competitive renewal o an R01 project, we will address these knowledge gaps through the application of nucleic acid chemistry coupled with techniques from structural biology and biochemistry. The results of these studies will extend our basic understanding of the process of RNA editing as well as lead to new methods for its control. Given our laboratory's recent discovery of small RNAs that react rapidly with isolated ADAR deaminase domains, we are in a position like never before to provide important information about the ADAR-RNA interaction. Thus, we will pursue X-ray diffraction quality crystals of ADAR deaminase domains in complex with RNAs derived from sequences shown by us to react rapidly and solve the structures in collaboration with Professor Andrew Fisher. We expect the resulting structures to reveal details of the ADAR-RNA interaction that will shed light on the observed editing site selectivity. In addition, we will directly test two competig hypotheses for the basis of editing site selectivity. In addition, to advance our goal of developin methods to control editing pharmacologically, we will generate new antisense oligonucleotides capable of regulating RNA editing in a site-specific manner (editing inhibitors and editing enhancers). The resulting compounds will be useful tools to probe the mechanism of the editing reaction, the biological function of specific editing events and could have long- term therapeutic potential. Finally, we will provide a deeper understanding of the ADAR reaction by identifying sites in the catalytic domain important for catalysis not previously appreciated by carrying out directed evolution to convert the hADAR3 catalytic domain into a functional RNA editing enzyme. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=9531375

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2206", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "3906468"
    }, 
    "description": "? DESCRIPTION (provided by applicant): The RNA editing ADAR enzymes convert adenosines to inosines in RNA. This phenomenon is widespread with > 15,000 A to I sites known in human transcripts. Since inosine is decoded as guanosine during translation, this modification can lead to changes in the meaning of codons (recoding). There are at least 50 different A to I sites in human mRNAs that cause recoding and recoding is common in the nervous system. Indeed, ADARs are necessary for a properly functioning nervous system and are known to regulate behavior in metazoans. Mutations in the human ADAR1 gene cause the skin disorder Dyschromatosis Symmetrica Hereditaria (DSH) and the autoimmune disease Aicardi-Goutieres Syndrome (AGS). Also, hyper editing has been observed at certain sites in cancer cells, such as in the mRNA for AZIN1 (antizyme inhibitor 1). In contrast however, hypo editing is observed in the glioma- associated ongene 1 (Gli1), a transcription factor important in the Hedgehog signaling pathway considered a therapeutic target in several types of cancer. Despite the significance of this form of regulation of RNA structure and function, our understanding of the mechanism of A to I editing is deficient. For instance, the selectivity for specific adenosines within ADAR substrates remains difficult to fully explain. Furthermore, pharmacological methods for controlling RNA editing at specific sites do not currently exist. In this competitive renewal o an R01 project, we will address these knowledge gaps through the application of nucleic acid chemistry coupled with techniques from structural biology and biochemistry. The results of these studies will extend our basic understanding of the process of RNA editing as well as lead to new methods for its control. Given our laboratory's recent discovery of small RNAs that react rapidly with isolated ADAR deaminase domains, we are in a position like never before to provide important information about the ADAR-RNA interaction. Thus, we will pursue X-ray diffraction quality crystals of ADAR deaminase domains in complex with RNAs derived from sequences shown by us to react rapidly and solve the structures in collaboration with Professor Andrew Fisher. We expect the resulting structures to reveal details of the ADAR-RNA interaction that will shed light on the observed editing site selectivity. In addition, we will directly test two competig hypotheses for the basis of editing site selectivity. In addition, to advance our goal of developin methods to control editing pharmacologically, we will generate new antisense oligonucleotides capable of regulating RNA editing in a site-specific manner (editing inhibitors and editing enhancers). The resulting compounds will be useful tools to probe the mechanism of the editing reaction, the biological function of specific editing events and could have long- term therapeutic potential. Finally, we will provide a deeper understanding of the ADAR reaction by identifying sites in the catalytic domain important for catalysis not previously appreciated by carrying out directed evolution to convert the hADAR3 catalytic domain into a functional RNA editing enzyme.", 
    "endDate": "2019-07-31T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.280785.0", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2516562", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2516562"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "R01GM061115"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "enzyme", 
      "instance", 
      "structural biology", 
      "recent discovery", 
      "phenomenon", 
      "catalysis", 
      "enhancer", 
      "specific sites", 
      "addition", 
      "ADARs", 
      "selectivity", 
      "specific editing events", 
      "compounds", 
      "codons", 
      "pharmacological methods", 
      "hADAR3 catalytic domain", 
      "detail", 
      "Bioorganic Chemistry", 
      "function", 
      "collaboration", 
      "cancer", 
      "inosine", 
      "technique", 
      "basis", 
      "catalytic domain", 
      "evolution", 
      "process", 
      "long- term", 
      "laboratory", 
      "several types", 
      "form", 
      "ADAR enzymes", 
      "knowledge gaps", 
      "translation", 
      "application", 
      "sites", 
      "competitive renewal o", 
      "competig hypotheses", 
      "goal", 
      "significance", 
      "nucleic acid chemistry", 
      "R01 project", 
      "transcription factors", 
      "specific adenosine", 
      "ADAR-RNA interaction", 
      "Professor Andrew Fisher", 
      "certain sites", 
      "sequence", 
      "position", 
      "contrast", 
      "functional RNAs", 
      "pathway", 
      "behavior", 
      "hyper editing", 
      "editing reaction", 
      "light", 
      "inhibitors", 
      "regulation", 
      "guanosine", 
      "human mRNAs", 
      "modification", 
      "meaning", 
      "antizyme inhibitor 1", 
      "isolated ADAR deaminase domains", 
      "understanding", 
      "site selectivity", 
      "ray diffraction quality crystals", 
      "changes", 
      "human ADAR1 gene", 
      "mutations", 
      "results", 
      "description", 
      "AGS", 
      "applicants", 
      "glioma-", 
      "important information", 
      "recoding", 
      "AZIN1", 
      "developin methods", 
      "therapeutic potential", 
      "therapeutic target", 
      "ADAR", 
      "useful tool", 
      "mRNA", 
      "nervous system", 
      "Gli1", 
      "site-specific manner", 
      "observed editing site selectivity", 
      "RNA editing", 
      "DSH", 
      "biochemistry", 
      "mechanism", 
      "Hedgehog", 
      "biological functions", 
      "lead", 
      "new method", 
      "deeper understanding", 
      "metazoans", 
      "ADAR deaminase domains", 
      "RNA", 
      "control", 
      "human transcripts", 
      "structure", 
      "ongene 1", 
      "hypo editing", 
      "ADAR reaction", 
      "cancer cells", 
      "basic understanding", 
      "small RNAs", 
      "RNA structure", 
      "new antisense oligonucleotide", 
      "study", 
      "adenosine"
    ], 
    "name": "The Bioorganic Chemistry of RNA editing by ADARs", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.27860.3b", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.27860.3b", 
          "name": "UNIVERSITY OF CALIFORNIA AT DAVIS", 
          "type": "Organization"
        }, 
        "familyName": "BEAL", 
        "givenName": "PETER A.", 
        "id": "sg:person.0642252420.64", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.0642252420.64", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2516562"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T12:17", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_9.xml.gz", 
    "startDate": "2000-04-01T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=9531375"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2516562'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2516562'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2516562'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2516562'


 

This table displays all metadata directly associated to this object as RDF triples.

157 TRIPLES      19 PREDICATES      135 URIs      127 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2516562 schema:about anzsrc-for:2206
2 schema:amount N992bcf9b6af340d5b890a5345342852d
3 schema:description ? DESCRIPTION (provided by applicant): The RNA editing ADAR enzymes convert adenosines to inosines in RNA. This phenomenon is widespread with > 15,000 A to I sites known in human transcripts. Since inosine is decoded as guanosine during translation, this modification can lead to changes in the meaning of codons (recoding). There are at least 50 different A to I sites in human mRNAs that cause recoding and recoding is common in the nervous system. Indeed, ADARs are necessary for a properly functioning nervous system and are known to regulate behavior in metazoans. Mutations in the human ADAR1 gene cause the skin disorder Dyschromatosis Symmetrica Hereditaria (DSH) and the autoimmune disease Aicardi-Goutieres Syndrome (AGS). Also, hyper editing has been observed at certain sites in cancer cells, such as in the mRNA for AZIN1 (antizyme inhibitor 1). In contrast however, hypo editing is observed in the glioma- associated ongene 1 (Gli1), a transcription factor important in the Hedgehog signaling pathway considered a therapeutic target in several types of cancer. Despite the significance of this form of regulation of RNA structure and function, our understanding of the mechanism of A to I editing is deficient. For instance, the selectivity for specific adenosines within ADAR substrates remains difficult to fully explain. Furthermore, pharmacological methods for controlling RNA editing at specific sites do not currently exist. In this competitive renewal o an R01 project, we will address these knowledge gaps through the application of nucleic acid chemistry coupled with techniques from structural biology and biochemistry. The results of these studies will extend our basic understanding of the process of RNA editing as well as lead to new methods for its control. Given our laboratory's recent discovery of small RNAs that react rapidly with isolated ADAR deaminase domains, we are in a position like never before to provide important information about the ADAR-RNA interaction. Thus, we will pursue X-ray diffraction quality crystals of ADAR deaminase domains in complex with RNAs derived from sequences shown by us to react rapidly and solve the structures in collaboration with Professor Andrew Fisher. We expect the resulting structures to reveal details of the ADAR-RNA interaction that will shed light on the observed editing site selectivity. In addition, we will directly test two competig hypotheses for the basis of editing site selectivity. In addition, to advance our goal of developin methods to control editing pharmacologically, we will generate new antisense oligonucleotides capable of regulating RNA editing in a site-specific manner (editing inhibitors and editing enhancers). The resulting compounds will be useful tools to probe the mechanism of the editing reaction, the biological function of specific editing events and could have long- term therapeutic potential. Finally, we will provide a deeper understanding of the ADAR reaction by identifying sites in the catalytic domain important for catalysis not previously appreciated by carrying out directed evolution to convert the hADAR3 catalytic domain into a functional RNA editing enzyme.
4 schema:endDate 2019-07-31T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.280785.0
6 schema:identifier N659ba4f28c44406aa95b0b7b28883a21
7 Nb05dba2bd1fb43cd889dec8151ebcf14
8 schema:inLanguage en
9 schema:keywords ADAR
10 ADAR deaminase domains
11 ADAR enzymes
12 ADAR reaction
13 ADAR-RNA interaction
14 ADARs
15 AGS
16 AZIN1
17 Bioorganic Chemistry
18 DSH
19 Gli1
20 Hedgehog
21 Professor Andrew Fisher
22 R01 project
23 RNA
24 RNA editing
25 RNA structure
26 addition
27 adenosine
28 antizyme inhibitor 1
29 applicants
30 application
31 basic understanding
32 basis
33 behavior
34 biochemistry
35 biological functions
36 cancer
37 cancer cells
38 catalysis
39 catalytic domain
40 certain sites
41 changes
42 codons
43 collaboration
44 competig hypotheses
45 competitive renewal o
46 compounds
47 contrast
48 control
49 deeper understanding
50 description
51 detail
52 developin methods
53 editing reaction
54 enhancer
55 enzyme
56 evolution
57 form
58 function
59 functional RNAs
60 glioma-
61 goal
62 guanosine
63 hADAR3 catalytic domain
64 human ADAR1 gene
65 human mRNAs
66 human transcripts
67 hyper editing
68 hypo editing
69 important information
70 inhibitors
71 inosine
72 instance
73 isolated ADAR deaminase domains
74 knowledge gaps
75 laboratory
76 lead
77 light
78 long- term
79 mRNA
80 meaning
81 mechanism
82 metazoans
83 modification
84 mutations
85 nervous system
86 new antisense oligonucleotide
87 new method
88 nucleic acid chemistry
89 observed editing site selectivity
90 ongene 1
91 pathway
92 pharmacological methods
93 phenomenon
94 position
95 process
96 ray diffraction quality crystals
97 recent discovery
98 recoding
99 regulation
100 results
101 selectivity
102 sequence
103 several types
104 significance
105 site selectivity
106 site-specific manner
107 sites
108 small RNAs
109 specific adenosine
110 specific editing events
111 specific sites
112 structural biology
113 structure
114 study
115 technique
116 therapeutic potential
117 therapeutic target
118 transcription factors
119 translation
120 understanding
121 useful tool
122 schema:name The Bioorganic Chemistry of RNA editing by ADARs
123 schema:recipient Nbec8a63a3e784343adc0e217c0be1424
124 sg:person.0642252420.64
125 https://www.grid.ac/institutes/grid.27860.3b
126 schema:sameAs https://app.dimensions.ai/details/grant/grant.2516562
127 schema:sdDatePublished 2019-03-07T12:17
128 schema:sdLicense https://scigraph.springernature.com/explorer/license/
129 schema:sdPublisher Ne3906323e0114640931214afca7fcc8a
130 schema:startDate 2000-04-01T00:00:00Z
131 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=9531375
132 sgo:license sg:explorer/license/
133 sgo:sdDataset grants
134 rdf:type schema:MonetaryGrant
135 N659ba4f28c44406aa95b0b7b28883a21 schema:name dimensions_id
136 schema:value 2516562
137 rdf:type schema:PropertyValue
138 N992bcf9b6af340d5b890a5345342852d schema:currency USD
139 schema:value 3906468
140 rdf:type schema:MonetaryAmount
141 Nb05dba2bd1fb43cd889dec8151ebcf14 schema:name nih_id
142 schema:value R01GM061115
143 rdf:type schema:PropertyValue
144 Nbec8a63a3e784343adc0e217c0be1424 schema:member sg:person.0642252420.64
145 schema:roleName PI
146 rdf:type schema:Role
147 Ne3906323e0114640931214afca7fcc8a schema:name Springer Nature - SN SciGraph project
148 rdf:type schema:Organization
149 anzsrc-for:2206 schema:inDefinedTermSet anzsrc-for:
150 rdf:type schema:DefinedTerm
151 sg:person.0642252420.64 schema:affiliation https://www.grid.ac/institutes/grid.27860.3b
152 schema:familyName BEAL
153 schema:givenName PETER A.
154 rdf:type schema:Person
155 https://www.grid.ac/institutes/grid.27860.3b schema:name UNIVERSITY OF CALIFORNIA AT DAVIS
156 rdf:type schema:Organization
157 https://www.grid.ac/institutes/grid.280785.0 schema:Organization
 




Preview window. Press ESC to close (or click here)


...